Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Nancy Stagliano
AddedMar 31, 2024
UpdatedMay 31, 2026
Nancy Stagliano

Nancy Stagliano

Board Member, Electra Therapeutics

CrunchbaseLinkedIn

Nancy Stagliano's Career

Electra Therapeutics
Electra Therapeutics

San Francisco, CA, US

Board Member· Board
Latigo Biotherapeutics
Latigo Biotherapeutics

Thousand Oaks, CA, US

Board Member· Board
Star Therapeutics
Star Therapeutics

South San Francisco, CA, US

Board Member· Board
Neuron23
Neuron23

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Nancy Stagliano's Career

Electra Therapeutics
Electra Therapeutics
Series B$100M302018San Francisco, CA, US
Board Member· Board

Leadership at Electra Therapeutics

Adam RosenthalAdam RosenthalFounder

Similar to Electra Therapeutics

EpiBiologicsEpiBiologicsSan Mateo, CA, USTargeted Therapiesest. 2022EpiBiologicsSan Mateo, CA, US · est. 2022

EpiBiologics: Pioneering antibody-based therapies targeting disease-driving proteins.

Series A · $73M38
AltruBioAltruBioLos Altos, CA, USAntibody Therapeuticsest. 2000AltruBioLos Altos, CA, US · est. 2000

AltruBio, a global biotech firm, develops targeted antibody therapeutics for cancer and immune diseases.

Series A · $102.6M5
Ernexa TherapeuticsErnexa TherapeuticsCambridge, MA, USCell Therapiesest. 1984Ernexa TherapeuticsCambridge, MA, US · est. 1984

Eterna Therapeutics: Pioneering cell engineering for cancer and immunologic disease treatment.

Public · $49.1M11
Star TherapeuticsStar TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2018Star TherapeuticsSouth San Francisco, CA, US · est. 2018

Star Therapeutics develops innovative therapies for rare diseases, focusing on novel biology and first-in-class antibody therapeutics.

Series C · $190M48
Latigo Biotherapeutics
Latigo Biotherapeutics
Series B$15M182018Thousand Oaks, CA, US
Board Member· Board

Leadership at Latigo Biotherapeutics

Scott WassermanScott WassermanCEO

Similar to Latigo Biotherapeutics

Concentric AnalgesicsConcentric AnalgesicsSan Francisco, CA, USTherapeuticsest. 2014Concentric AnalgesicsSan Francisco, CA, US · est. 2014

Concentric Analgesics, Inc.: A biotech firm innovating non-opioid solutions for acute and chronic pain.

Series B · $103.1M22
NeurocarrusNeurocarrusMonterey, CA, USDrug Deliveryest. 2015NeurocarrusMonterey, CA, US · est. 2015

Neurocarrus: Innovating non-addictive, pain-disrupting drug delivery technology.

Seed · $100k8
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Centrexion TherapeuticsCentrexion TherapeuticsBoston, MA, USPain Therapiesest. 2013Centrexion TherapeuticsBoston, MA, US · est. 2013

US-based Centrexion Therapeutics develops non-opioid, non-addictive therapies for chronic pain treatment.

Public · $229.2M22
Star Therapeutics
Star Therapeutics
Series C$190M482018South San Francisco, CA, US
Board Member· Board
Neuron23
Neuron23
Series C$213.5M612018South San Francisco, CA, US
Board Member· Board

Leadership at Neuron23

Michael AlmstetterMichael AlmstetterBoard Member
Kathy DongKathy DongBoard Member
Jim ScopaJim ScopaBoard Member
Adam KnightAdam KnightFounder

Similar to Neuron23

Nido BiosciencesNido BiosciencesBoston, MA, USPrecision Medicinesest. 2018Nido BiosciencesBoston, MA, US · est. 2018

Nido Bio: Developing precision medicines for severe neurological diseases using advanced neuroscience.

Series B · $109M30
NeuronityNeuronityMansfield, MA, USMedical Researchest. 2022NeuronityMansfield, MA, US · est. 2022

Neuronity: A Massachusetts-based medical organization curing neurological disorders since 2022.

Pre-Seed · $780k5
Neurona TherapeuticsNeurona TherapeuticsSouth San Francisco, CA, USCell Therapiesest. 2008Neurona TherapeuticsSouth San Francisco, CA, US · est. 2008

Neurona Therapeutics: Leading provider of cell-based medicines for neurological disorders.

Series A · $200.3M58
Neuro42Neuro42Oakland, CA, USMedical Devicesest. 2020Neuro42Oakland, CA, US · est. 2020

neuro42: Innovating advanced MRI tech for diagnosing and treating neurological conditions.

Series B · $12.8M26

Nancy Stagliano's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Nancy Stagliano

Shadrach Benny RetnamonyShadrach Benny RetnamonyCo-Founder · NeuronStephen NaylorStephen NaylorBoard Member · ReNeuroGenNiken PatelNiken PatelFounder · Neuron7Sandra PanemSandra PanemBoard Member · Acorda TherapeuticsKevin DerrKevin DerrCo-Founder · NeuronSphere